HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Replimune Group (NASDAQ:REPL) and raised the price target from $12 to $17, indicating increased confidence in the company's future performance.
June 07, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Replimune Group and raised the price target from $12 to $17, indicating increased confidence in the company's future performance.
The raised price target from $12 to $17 by HC Wainwright & Co. suggests a positive outlook for Replimune Group, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100